Ab Science Sa has released a press release.
AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
Earlier from Ab Science Sa
- AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
- AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
- AB Science: Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share